Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 20/20 | 0.66 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2514970 | 1.00 | CALCRL (0.66) | CALCRLADRB2CYP3A4 | |
| SCHEMBL1672790 | 0.90 | CALCRL (0.80) | CALCRLADRB2CYP3A4 | |
| SCHEMBL2519432 | 0.90 | CALCRL (0.80) | CALCRLADRB2CYP3A4 | |
| SCHEMBL1672793 | 0.90 | CALCRL (0.80) | CALCRLADRB2CYP3A4 | |
| SCHEMBL1670998 | 0.89 | CALCRL (0.79) | CALCRLADRB2CYP3A4 | |
| SCHEMBL2520369 | 0.89 | CALCRL (0.79) | CALCRLADRB2CYP3A4 | |
| SCHEMBL1671002 | 0.89 | CALCRL (0.79) | CALCRLADRB2CYP3A4 | |
| SCHEMBL1672923 | 0.89 | CALCRL (0.81) | CALCRLADRB2CYP3A4 | |
| SCHEMBL1672921 | 0.89 | CALCRL (0.81) | CALCRLADRB2CYP3A4 | |
| SCHEMBL14716634 | 0.85 | CALCRL (0.80) | CALCRLADRB2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130053570-A1 | CGRP Receptor Antagonists | BRISTOL MYERS SQUIBB CO (US) | 2013-02-28 | — | — | US | disclosed |
| US-8314117-B2 | CGRP receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-20 | — | — | US | disclosed |
| US-20110251223-A1 | CGRP Receptor Antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2011-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053570-A1 | CGRP Receptor Antagonists | CALCRL, BDKRB2, CALCR | CALCRL 1/4885ADRB2 44/4885CYP3A4 2984/4885 |
| US-20110251223-A1 | CGRP Receptor Antagonists | CALCRL, BDKRB2, CALCR | CALCRL 1/4885ADRB2 44/4885CYP3A4 2984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.